# The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

> **NCT02792400** · NA · COMPLETED · sponsor: **University Hospital, Gentofte, Copenhagen** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** LY2403021
- **DRUG:** LY2403021 placebo
- **PROCEDURE:** Standardised liquid meal
- **DRUG:** Linagliptin
- **DRUG:** Linagliptin placebo
- **DRUG:** Empagliflozin
- **DRUG:** Empagliflozin placebo

## Key facts

- **NCT ID:** NCT02792400
- **Lead sponsor:** University Hospital, Gentofte, Copenhagen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-08
- **Final completion:** 2018-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02792400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02792400, "The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT02792400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*